Research paperLovastatin therapy in familial dysbetalipoproteinemia: Effects on kinetics of apolipoprotein B
References (36)
- et al.
Human E apoprotein heterogeneity: cysteine-arginine interchange in amino acid sequence of the apo E isoforms
J. Biol. Chem.
(1981) - et al.
Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site
J. Biol. Chem.
(1982) - et al.
Type III hyperlipoproteinemia. Rise in high-density lipoprotein levels in response to therapy
Am. J. Med.
(1979) - et al.
Effects of estrogen therapy on apolipoprotein E in Type III hyperlipoproteinemia
Metabolism
(1979) - et al.
Preliminary Report: Treatment of type 3 hyperlipoproteinemia with mevinolin
Metabolism
(1986) Triglyceride determination after enzymatic hydrolysis
- et al.
Increased catabolism of VLDLapolipoprotein B and synthesis of bile acids in a case of hypobetalipoproteinemia
Metabolism
(1987) The formation of LDL: mechanisms and regulation
J. Lipid Res.
(1984)- et al.
Effects of interruption of the enterohepatic circulation of bile acids on the transport of very low density lipoproteintriglycerides
Metabolism
(1982) - et al.
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia
J. Lipid Res.
(1985)
Familial type 3 hyperlipoproteinemia (dysbetalipoproteinemia)
Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man
Nature
Human apolipoprotein E isoprotein subclasses are genetically determined
Am. J. Hum. Genet.
Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts, and membranes from liver, and adrenal of rats, rabbits, and cows
J. Clin. Invest.
Remnants of lipoproteins of intestinal and hepatic origin in familial dysbetalipoproteinemia
Arteriosclerosis
Polymorphism of apolipoprotein E. II. Genetics of hyperlipoproteinemia type III
Clin. Genet.
Dietary and drug treatment of dysbetalipoproteinemia. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment
Ann. Intern. Med.
The efficacy of clofibrate (CPIB) in familial hyperlipoproteinemia
Cited by (67)
Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: Result from a crossover study
2011, Clinica Chimica ActaCitation Excerpt :3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitors, statins, reduce blood cholesterol by increasing LDL receptors on hepatocytes through inhibition of cholesterol biosynthesis [8]. Although type III HLP presents hypo-LDL-cholesterolemia, statins also effectively reduce remnant lipoproteins in this dyslipidemia [9,10]. Recently it was shown that strong statin reduces triglycerides by almost the same degree as it does with LDL cholesterol in type III HLP [11,12].
Effect of apolipoprotein E genotype on apolipoprotein B-100 metabolism in normolipidemic and hyperlipidemic subjects
2010, Journal of Lipid ResearchCitation Excerpt :Earlier studies suggest that particles in this pool may correspond to β-VLDL particles (28, 29). The greater proportion of VLDL particles in the slowly turning over VLDL pool, exclusively in apoE2/E2 subjects with type III hyperlipidemia, suggest that this may be a key mechanism in the expansion of plasma β-VLDL pool (30). Furthermore, the increased proportion of VLDL apoB in the slowly turning over VLDL pool is an independent determinant, together with VLDL apoB concentrations, of VLDL cholesterol levels.
History and Biochemistry of Statins
2004, Statins: Understanding Clinical Use